Linkage Biosciences Awarded NHS Contract
News Aug 30, 2016
The new tissue typing platform, including Real-Time PCR instrumentation, will be installed and adopted by various laboratories across the country.
Dr. Andrea Harmer, National Head of NHS Blood and Transplant H&I Services, said, “At NHS Blood and Transplant, we were looking for the best technology available for our rapid typing requirements. We developed a comprehensive matrix to evaluate multiple platforms and were extremely pleased with the results from Linkage Biosciences. The laboratory tests performed by our scientists showed the product to be simple to use, fast, and robust.”
“We are excited to partner with NHS Blood and Transplant and support the fast-growing adoption of LinkSēq tissue typing technology,” said Zachary Antovich, Chief Executive Officer of Linkage Biosciences. “The technical advantages of LinkSēq, as supported by all the necessary evidence during the evaluation period, clearly established the superiority of our offering. The decision of the UK’s NHS Blood and Transplant to select our product is the outcome of a thorough evaluation of the competitive landscape and we suspect other nations will view this tender as a benchmark for their own assessment.”
LinkSēq offers a dramatically simplified workflow for detecting Human Leukocyte Antigen (HLA) genes associated with tissue compatibility for organ transplantation. With less than 10 minutes of set-up and no further operator intervention, LinkSēq provides complete molecular genotyping results in as little as 90 minutes. Its simple workflow avoids post-amplification contamination, as well as allowing rapid turnaround time and increased laboratory productivity.
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018